Centessa Pharmaceuticals (CNTA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kelly Shi from Jefferies upgraded the rating on the stock to a Buy and gave it a $11.00 price target.
Kelly Shi has given her Buy rating due to several compelling factors associated with Centessa Pharmaceuticals’ operations and potential growth. The strength of Centessa Pharmaceuticals lies in its diversified pipeline of unique and differentiated assets. The pharmaceutical firm has developed ORX750, a highly potent OX2R agonist, which shows promise in the treatment of narcolepsy. ORX750 is projected to be a major catalyst in their growth with its point of care data expected in 2024. The drug’s unique design and high efficacy potentially translate to a low daily dose in clinical trials, contributing to its market appeal. Shi also recognizes the potential market opportunity presented by the OX2R biology.
Another factor contributing to Shi’s positive rating is the development of SerpinPC, a drug designed to facilitate coagulation without relying on FVIII/IX. This could make it a broad-spectrum treatment for hemophilia, beneficial for patients with and without inhibitors. Its less frequent administration requirement compared to current treatment options and its promising safety profile further enhance its potential. Shi also notes the potential upside presented by Centessa’s LockBody platform candidates LB101 and LB206, which could validate their proprietary LockBody technology and open up opportunities in the oncology space. Overall, Shi’s Buy rating is based on Centessa’s robust and diversified pipeline, the potential market opportunities for their drugs, and their promising ongoing studies.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Centessa Pharmaceuticals (CNTA) Company Description:
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
Read More on CNTA:
- Centessa reports Q3 EPS (40c), consensus (52c)
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
- CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
- Centessa announces dosing of first subject in registrational PRESent-3 study
